Variable | Participants | |
---|---|---|
n = 60 | ||
n | % | |
Number of patients with breast cancer, NHL, NSCLC and/or colorectal cancer seen in one-month a | 150 (50–300) | |
Percentage of patients with breast cancer, NHL, NSCLC and/or colorectal cancer with pegfilgrastim b | 60,3 (25,6) | 70 (40–80) |
Options for pegfilgrastim administration that have been used by physicians | ||
Same day as myelosuppressive chemotherapy, in the clinic, by a HCP | 40 | 66,7 |
Administered when the patient returns to the clinic, 24 h after myelosuppressive chemotherapy, specifically to receive an injection of pegfilgrastim from a HCP | 48 | 80 |
Administered when the patient returns to the clinic, 48–72 h after myelosuppressive chemotherapy, specifically to receive an injection of pegfilgrastim from a HCP | 25 | 41,7 |
Home administration using Neulastim (OBI) that has been attached to the patient’s arm or abdomen in the clinic; approximately 24 h (just over 1 day) after myelosuppressive chemotherapy | 47 | 78,3 |